Nutromics CEO and co-founder Peter Vranes joined Ray Crowley on Investment Research Radio. Nutromics' first product focuses on vancomycin, a powerful antibiotic widely used in hospitals to treat serious infections, including MRSA and sepsis. Because vancomycin has a narrow therapeutic window, clinicians must carefully balance effective dosing against the risk of toxicity, including kidney injury. Nutromics is developing a wearable sensor that continuously measures drug concentrations in the fluid beneath the skin, potentially helping clinicians make faster, more informed dosing decisions while reducing reliance on repeated blood draws.
They discuss the clinical development underway, the potential benefits for hospital workflows and patient care, and the significance of the FDA granting the company's Vancomycin Therapeutic Drug Monitoring Patch Breakthrough Device Designation in September 2026. The designation supports regulatory engagement but does not constitute FDA marketing approval.
Beyond antibiotic dosing, they explore Nutromics' longer-term vision for its Lab-on-a-Patch technology: wearable microneedle sensors capable of measuring multiple drugs and biomarkers simultaneously. Future applications could include monitoring indicators associated with sepsis, kidney injury, inflammation, and cardiovascular disease.